Understanding how autoantibodies in scleroderma relate to cancer risk
Autoantibodies define scleroderma subgroups with distinct relationships to cancer
['FUNDING_R01'] · JOHNS HOPKINS UNIVERSITY · NIH-10981317
This study is looking at how certain immune markers in people with scleroderma might help us understand their risk of developing cancer, so we can better support patients based on their unique profiles.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10981317 on ClinicalTrials.gov |
What this research studies
This research investigates the connections between scleroderma and cancer by examining specific autoantibodies in patients. It aims to identify different subgroups of scleroderma patients based on their autoantibody profiles, which may indicate varying risks for developing cancer. By analyzing data and biospecimens from well-characterized cohorts, the study seeks to determine how these autoantibodies can be used for cancer risk stratification and to understand the broader implications of autoimmunity in cancer emergence. Patients may be monitored over time to see how their immune responses and clinical outcomes change in relation to cancer diagnosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with scleroderma who have specific autoantibody profiles.
Not a fit: Patients with scleroderma who do not have detectable autoantibodies or those with other autoimmune conditions unrelated to scleroderma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer risk assessment and tailored management strategies for scleroderma patients.
How similar studies have performed: Previous research has indicated promising connections between autoantibodies and cancer risk in autoimmune diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHAH, AMI AALOK — JOHNS HOPKINS UNIVERSITY
- Study coordinator: SHAH, AMI AALOK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.